Ravi Rao stands out as a venture partner who also actively runs companies, holding Chief Medical Officer roles at Sitryx Therapeutics and Oxford Biomedica and a board seat at DBV Technologies while working at Dementia Discovery Fund, after a career that moved from treating patients as a rheumatologist at Hammersmith Hospital to leading drug development at Roche/Genentech, GSK, Aeglea, and Sobi. His deepest expertise is in immunology and immunometabolism, and at Sitryx he speaks directly about the science behind an oral treatment meant to rebalance the immune system in atopic dermatitis, showing he stays closely involved in the actual medical strategy rather than just overseeing investments from a distance.